AstraZeneca

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.

About AZN

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. 

CEO
Pascal Soriot
CEOPascal Soriot
Employees
96,100
Employees96,100
Headquarters
Cambridge, Cambridgeshire
HeadquartersCambridge, Cambridgeshire
Founded
1913
Founded1913
Employees
96,100
Employees96,100

AZN Key Statistics

Market cap
251.39B
Market cap251.39B
Price-Earnings ratio
24.15
Price-Earnings ratio24.15
Dividend yield
1.93%
Dividend yield1.93%
Average volume
3.27M
Average volume3.27M
High today
$163.75
High today$163.75
Low today
$161.95
Low today$161.95
Open price
$162.86
Open price$162.86
Volume
2.72M
Volume2.72M
52 Week high
$212.71
52 Week high$212.71
52 Week low
$145.79
52 Week low$145.79

Stock Snapshot

As of today, AstraZeneca(AZN) shares are valued at $162.05. The company's market cap stands at 251.39B, with a P/E ratio of 24.15 and a dividend yield of 1.93%.

On 2026-08-31, AstraZeneca(AZN) stock moved within a range of $161.95 to $163.75. With shares now at $162.05, the stock is trading +0.1% above its intraday low and -1.0% below the session's peak.

Trading activity shows a volume of 2.72M, compared to an average daily volume of 3.27M.

Over the past 52 weeks, AstraZeneca(AZN) stock has traded between a high of $212.71 and a low of $145.79.

Over the past 52 weeks, AstraZeneca(AZN) stock has traded between a high of $212.71 and a low of $145.79.

AZN News

TipRanks 5h
AstraZeneca’s PROGRESS-CKD Study Completes in Kazakhstan, Sharpening Real‑World Kidney Care Insights

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. The Prospective Observational Multicenter Study of Patients With Arterial Hypertension...

TipRanks 8h
AstraZeneca gets FDA orphan designation for treatment of esophageal cancer

AstraZeneca (AZN) Pharmaceuticals’ sonesitatug vedotin was granted FDA orphan designation as a treatment of esophageal cancer, according to a post to the agency...

TipRanks 11h
AstraZeneca’s LUMINARA Data Validate Relaxin Mechanism, Supporting Tectonic’s TX45 Program and Unchanged $88 Price Target Buy Rating

LifeSci Capital analyst Gaurav Maini maintained a Buy rating on Tectonic Therapeutic today and set a price target of $88.00. Gaurav Maini has given his Buy rati...

Analyst ratings

100%

of 10 ratings
Buy
100%
Hold
0%
Sell
0%

More AZN News

Investor's Business Daily 14h
One Of Amgen's Biggest Moneymakers Cuts The Risk Of Dying By 20%

Amgen, AstraZeneca Score With Tezspire; Can They Take On Dupixent? 8/27/2026 Amgen and AstraZeneca's drug, Tezspire, scored Thursday in an esophageal disease t...

One Of Amgen's Biggest Moneymakers Cuts The Risk Of Dying By 20%
Nasdaq 2d
Opinion: Bristol Myers Squibb Is a Buy -- but the Real Reason Why Might Surprise Investors

Key Points Bristol Myers Squibb's cardiovascular drug Eliquis is set to lose patent protection in 2028. The company is busy bringing out new drugs and develop...

Opinion: Bristol Myers Squibb Is a Buy -- but the Real Reason Why Might Surprise Investors
CNN 3d
AZN Stock Quote Price and Forecast - CNN

...

AZN Stock Quote Price and Forecast - CNN
TipRanks 4d
AstraZeneca Targets Pediatric Asthma Gains With New Glycopyrronium Trial

AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. AstraZeneca plc (AZN) is running a Phase II trial called “A Phase II, Randomized,...

TipRanks 4d
AstraZeneca Advances Off‑the‑Shelf CAR‑T Program in Tough‑to‑Treat Multiple Myeloma

AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. AstraZeneca (AZN) is advancing a new study of AZD4045 in adults with relapsed or...

TipRanks 4d
AstraZeneca’s CREW Study: Real-World Tezspire Data That Could Shape Respiratory Revenues

AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. The CREW Study from AstraZeneca focuses on patients in Japan with chronic rhinosi...

Nasdaq 4d
AZN/AMGN's Tezspire Hits Primary Goal in Eosinophilic Esophagitis Study

AstraZeneca AZN and its partner Amgen AMGN jointly announced positive top-line data from the late-stage CROSSING study, which evaluated Tezspire (tezepelumab) i...

AZN/AMGN's Tezspire Hits Primary Goal in Eosinophilic Esophagitis Study

People also own

Based on the portfolios of people who own AZN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.